Basel, Switzerland · Est. 1896 · 100,000 employees
Global pioneer in pharmaceuticals and diagnostics.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 9 drugs with upcoming expirations
Pipeline
By Phase
77 drugs in development
By Therapeutic Area
top 6
R&D Momentum
100/100
Pipeline Velocity
82/100
Trial Completion Rate
87/100
Pipeline Concentration
26/100
Pipeline Freshness
64/100
Strategic Signals
Activity
Last 14 days
A Phase IIIb, Single-Arm, Open-Label Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes (PRO) of Giredestrant in Patients With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy
A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
A Multicenter, International, Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
A Non-Interventional, Multicenter, Multicohort Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Subcutaneous Atezolizumab in Participants Treated in Routine Clinical Practice
Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition
A Phase I, Multicenter, Open-Label, Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 Administered by Intravitreal Injection as Monotherapy and in Combination With Faricimab in Patients With Diabetic Macular Edema
A Multicenter, Open-Label, Expanded Access Program to Provide Divarasib to Patients With Previously Treated KRAS G12c-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)
A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab Monotherapy and Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
An Open-Label, Multicenter, Phase Ia/b Study Evaluating the Safety and Pharmacokinetics of RO7851624 in Patients With Relapsed/Refractory Multiple Myeloma
A Phase III, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Prophylaxis in Patients With Type 3 Von Willebrand Disease
Details
Company Overview
$240.0B
Mkt Cap
$58.7B
Revenue
$8.4B
Cash
Therapeutic Focus
Pipeline
Regulatory
Gazyva — GAZYVA
Application BLA125486
Rezzayo — REZZAYO
Application NDA217417
Actemra — ACTEMRA
Application BLA125276
Actemra — ACTEMRA
Application BLA125472
Gazyva — GAZYVA
Application BLA125486
Gazyva — GAZYVA
Application BLA125486
Actemra — ACTEMRA
Application BLA125276
Cotellic — COTELLIC
Application NDA206192
CellCept — CELLCEPT
Application NDA050722
CellCept — CELLCEPT
Application NDA050722
CellCept — CELLCEPT
Application NDA050723
CellCept — CELLCEPT
Application NDA050723
CellCept — CELLCEPT
Application NDA050758
CellCept — CELLCEPT
Application NDA050758
CellCept — CELLCEPT
Application NDA050759
CellCept — CELLCEPT
Application NDA050759
Rezzayo — REZZAYO
Application NDA217417
Perjeta — PERJETA
Application BLA125409
Vabysmo — VABYSMO
Application BLA761235
Actemra — AVTOZMA
Application BLA761498 (BLA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)